selecta
biosciences
reports
third
quarter
financial
results
provides
corporate
updates
phase
dissolve
clinical
program
sobi
ongoing
evaluate
topline
data
expected
second
half
ind
filing
gene
therapy
expected
preliminary
phase
data
expected
end
iga
nephropathy
program
underway
ind
expected
end
ended
quarter
cash
position
million
runway
first
quarter
company
host
conference
call
today
et
watertown
globe
newswire
selecta
biosciences
nasdaq
selb
biotechnology
company
leveraging
clinically
validated
platform
develop
tolerogenic
therapies
selectively
mitigate
unwanted
immune
responses
today
announced
financial
results
third
quarter
ended
september
provided
corporate
updates
past
quarter
productive
team
continued
progress
clinical
programs
said
carsten
brunn
president
ceo
selecta
reported
topline
data
phase
compare
trial
demonstrated
potential
immtor
platform
combined
highly
immunogenic
enzyme
commenced
phase
dissolve
program
partnership
sobi
look
forward
continuing
build
pipeline
gene
therapy
programs
mma
otc
deficiency
second
enzyme
program
iga
nephropathy
strategy
focused
leveraging
immtor
amplify
efficacy
biologic
therapies
restore
autoimmune
recent
highlights
anticipated
upcoming
milestones
two
key
clinical
milestones
september
selecta
sobi
commenced
phase
clinical
program
known
dissolve
selecta
running
program
sobi
reimbursing
selecta
costs
associated
program
dissolve
clinical
program
consists
two
trials
evaluated
two
doses
immtor
mg
kg
mg
kg
one
dose
pegadricase
mg
kg
studies
trial
aim
enroll
patients
dose
level
placebo
dissolve
safety
efficacy
evaluated
six
months
extension
dissolve
ii
assess
safety
efficacy
time
point
extension
primary
endpoint
studies
serum
uric
acid
levels
sua
less
mg
dl
six
months
measure
disease
severity
chronic
refractory
gout
topline
data
dissolve
program
expected
second
half
also
september
company
reported
topline
results
phase
compare
clinical
trial
dose
immtor
pegadricase
compared
biweekly
doses
pegloticase
sobi
assumes
responsibility
development
excluding
dissolve
run
selecta
funded
sobi
regulatory
commercial
activities
expenses
markets
outside
china
selecta
eligible
receive
potential
development
regulatory
commercial
milestone
payments
million
tiered
royalties
net
sales
september
selecta
sobi
commenced
phase
clinical
program
known
dissolve
selecta
running
program
sobi
reimbursing
selecta
costs
associated
program
dissolve
clinical
program
consists
two
trials
evaluated
two
doses
immtor
mg
kg
mg
kg
one
dose
pegadricase
mg
kg
studies
trial
aim
enroll
patients
dose
level
placebo
dissolve
safety
efficacy
evaluated
six
months
extension
dissolve
ii
assess
safety
efficacy
time
point
extension
primary
endpoint
studies
serum
uric
acid
levels
sua
less
mg
dl
six
months
measure
disease
severity
chronic
refractory
gout
topline
data
dissolve
program
expected
second
half
also
september
company
reported
topline
results
phase
compare
clinical
trial
dose
immtor
pegadricase
compared
biweekly
doses
pegloticase
sobi
assumes
responsibility
development
excluding
dissolve
run
selecta
funded
sobi
regulatory
commercial
activities
expenses
markets
outside
china
selecta
eligible
receive
potential
development
regulatory
commercial
milestone
payments
million
tiered
royalties
net
sales
granted
rare
pediatric
disease
designation
askbio
gene
therapy
methylmalonic
acidemia
selecta
askbio
received
rare
pediatric
disease
designation
food
drug
administration
fda
develop
combination
immtor
treatment
isolated
methylmalonic
acidemia
mma
due
mutase
mmut
gene
mutations
selecta
askbio
expect
commence
phase
clinical
trial
program
first
half
preliminary
data
expected
end
selecta
askbio
received
rare
pediatric
disease
designation
food
drug
administration
fda
develop
combination
immtor
treatment
isolated
methylmalonic
acidemia
mma
due
mutase
mmut
gene
mutations
selecta
askbio
expect
commence
phase
clinical
trial
program
first
half
preliminary
data
expected
end
entered
research
license
option
agreement
igan
biosciences
use
immtor
iga
nephropathy
october
selecta
igan
biosciences
reached
agreement
provides
selecta
option
exclusive
license
rights
develop
commercialize
immtor
platform
combination
igan
immunoglobulin
iga
protease
treatment
iga
nephropathy
igan
selecta
intends
submit
investigational
new
drug
application
ind
iga
nephropathy
end
iga
nephropathy
characterized
deposition
immunoglobulin
glomerular
mesangium
leading
contributor
development
chronic
kidney
disease
renal
failure
approved
therapies
treatment
igan
third
quarter
financial
results
cash
position
selecta
million
cash
cash
equivalents
restricted
cash
september
compares
cash
cash
equivalents
restricted
cash
million
december
selecta
believes
available
cash
cash
equivalents
restricted
cash
september
enable
selecta
fund
operating
expenses
capital
expenditure
requirements
first
quarter
net
cash
provided
operating
activities
million
nine
months
ended
september
compared
million
used
period
revenue
revenue
recognition
third
quarter
million
three
months
ended
september
recognized
million
license
agreement
sobi
resulting
shipment
clinical
supply
reimbursement
costs
incurred
phase
dissolve
clinical
program
million
shipments
collaboration
agreement
sarepta
three
months
ended
september
selecta
recognize
revenue
research
development
expenses
research
development
expenses
third
quarter
million
compares
million
period
increase
cost
primarily
result
initiation
phase
dissolve
clinical
program
costs
subject
cost
reimbursement
arrangement
license
sobi
increase
expense
also
result
completion
phase
compare
trial
askbio
collaboration
research
development
expenses
third
quarter
million
compares
million
period
increase
cost
primarily
result
initiation
phase
dissolve
clinical
program
costs
subject
cost
reimbursement
arrangement
license
sobi
increase
expense
also
result
completion
phase
compare
trial
askbio
collaboration
general
administrative
expenses
general
administrative
expenses
third
quarter
million
compares
million
period
increase
costs
result
expenses
incurred
facilities
legal
professional
fees
offset
decreased
travel
expense
general
administrative
expenses
third
quarter
million
compares
million
period
increase
costs
result
expenses
incurred
facilities
legal
professional
fees
offset
decreased
travel
expense
net
loss
third
quarter
selecta
reported
net
loss
million
per
share
compared
net
loss
million
per
share
period
conference
call
webcast
reminder
selecta
management
host
conference
call
et
today
provide
corporate
update
review
company
third
quarter
financial
results
individuals
may
participate
live
call
via
telephone
dialing
domestic
international
may
access
teleconference
replay
one
week
dialing
domestic
international
using
confirmation
code
investors
public
access
live
archived
webcast
call
via
investors
media
section
company
website
selecta
biosciences
selecta
biosciences
nasdaq
selb
leveraging
clinically
validated
platform
develop
tolerogenic
therapies
selectively
mitigate
unwanted
immune
responses
observed
ability
induce
tolerance
highly
immunogenic
proteins
immtor
potential
amplify
efficacy
biologic
therapies
including
redosing
gene
therapies
well
restore
body
natural
autoimmune
diseases
company
first
program
aimed
addressing
immunogenicity
aav
gene
therapies
expected
enter
clinical
trials
early
collaboration
askbio
treatment
methylmalonic
acidemia
mma
rare
metabolic
disorder
program
focused
addressing
iga
nephropathy
driven
immtor
therapeutic
enzyme
also
development
among
additional
product
candidates
selecta
recently
licensed
phase
clinical
product
candidate
chronic
refractory
gout
sobi
information
please
visit
statements
statements
press
release
future
expectations
plans
prospects
selecta
biosciences
company
including
without
limitation
statements
regarding
potential
safety
efficacy
company
product
candidates
design
progress
timing
availability
results
company
clinical
trials
including
respect
phase
dissolve
clinical
program
planned
clinical
trial
planned
regulatory
filings
submissions
timing
thereof
potential
company
immtor
technology
platform
generally
technology
platforms
collaboration
partners
sufficiency
company
cash
cash
equivalents
restricted
cash
fund
operating
expenses
capital
expenditure
requirements
statements
containing
words
anticipate
believe
continue
could
estimate
expect
hypothesize
intend
may
plan
potential
predict
project
target
would
similar
expressions
constitute
statements
within
meaning
private
securities
litigation
reform
act
actual
results
may
differ
materially
indicated
statements
result
various
important
factors
including
limited
following
uncertainties
inherent
initiation
completion
cost
clinical
trials
including
proof
concept
trials
including
uncertain
outcomes
availability
timing
data
ongoing
future
clinical
trials
results
trials
whether
preliminary
results
particular
clinical
trial
predictive
final
results
trial
whether
results
early
clinical
trials
indicative
results
later
clinical
trials
unproven
approach
company
immtor
technology
potential
delays
enrollment
patients
undesirable
side
effects
company
product
candidates
reliance
third
parties
manufacture
product
candidates
conduct
clinical
trials
company
inability
maintain
existing
future
collaborations
licenses
contractual
relationships
inability
protect
proprietary
technology
intellectual
property
potential
delays
regulatory
approvals
availability
funding
sufficient
foreseeable
unforeseeable
operating
expenses
capital
expenditure
requirements
effect
pandemic
company
specifically
clinical
trials
manufacturing
operations
company
recurring
losses
operations
negative
cash
flows
operations
raise
substantial
doubt
regarding
ability
continue
going
concern
substantial
fluctuation
price
common
stock
important
factors
discussed
risk
factors
section
company
recent
quarterly
report
form
filings
company
makes
securities
exchange
commission
addition
statements
included
press
release
represent
company
views
date
publication
relied
upon
representing
views
subsequent
date
company
specifically
disclaims
intention
update
statements
included
press
release
selecta
biosciences
subsidiaries
consolidated
balance
sheets
amounts
thousands
except
share
data
par
value
september
december
unaudited
assets
current
assets
cash
cash
equivalents
restricted
cash
accounts
receivable
prepaid
expenses
current
assets
total
current
assets
property
equipment
net
asset
net
restricted
cash
assets
total
assets
liabilities
stockholders
deficit
equity
current
liabilities
accounts
payable
accrued
expenses
loan
payable
lease
liability
deferred
revenue
total
current
liabilities
liabilities
loan
payable
net
current
portion
lease
liability
deferred
revenue
warrant
liabilities
total
liabilities
stockholders
deficit
equity
preferred
stock
par
value
shares
authorized
shares
issued
outstanding
september
december
respectively
common
stock
par
value
shares
authorized
shares
issued
outstanding
september
december
respectively
additional
capital
accumulated
deficit
accumulated
comprehensive
loss
total
stockholders
deficit
equity
total
liabilities
stockholders
deficit
equity
selecta
biosciences
subsidiaries
consolidated
statements
operations
comprehensive
loss
amounts
thousands
except
share
data
per
share
data
three
months
ended
september
nine
months
ended
september
unaudited
grant
collaboration
revenue
operating
expenses
research
development
general
administrative
total
operating
expenses
loss
operations
investment
income
loss
extinguishment
debt
foreign
currency
transaction
loss
net
interest
expense
change
fair
value
warrant
liabilities
income
expense
net
net
loss
comprehensive
loss
foreign
currency
translation
adjustment
unrealized
gain
securities
total
comprehensive
loss
net
loss
per
share
basic
diluted
weighted
average
common
shares
outstanding
basic
diluted
investors
lee
stern
solebury
trout
lstern
